By Doug Macron
Alnylam Pharmaceuticals last week shot back at Tekmira Pharmaceuticals in an ongoing patent-infringement suit between the companies, arguing that Tekmira's motion to dismiss the case is “unfounded” and ignores “well-settled law.”
A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.
Try GenomeWeb Premium now.
Already a GenomeWeb Premium member? Login Now. Or, See if your institution qualifies for premium access.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.
Hong Kong is using DNA phenotyping to shame litterers.
A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.
NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.